文献速递泌尿男性生殖肿瘤

CISTO研究12个月结果:复发高级别非肌层浸润性膀胱癌根治性膀胱切除与保膀胱治疗的比较

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
PubMed 文献 · J Clin Oncol · 2025-12-15

CISTO是一项务实前瞻性观察队列研究,纳入570例既往接受过BCG诱导且12个月内治疗的复发高级别NMIBC患者,患者自主选择根治性膀胱切除(RC,199例)或保膀胱治疗(BST,371例)。

要点

  • 12个月时RC与BST的体力功能无显著差异
  • RC在情绪、总体生活质量及经济负担方面更优
  • BST在肠道和性健康方面更优,肿瘤特异性生存相近

核心结论

  • 多数患者优先关注的结果在選擇RC者中相似或更优,支持RC在复发高级别NMIBC治疗中继续发挥作用。

研究设计与样本

  • 务实前瞻性观察队列研究,由患者选择并优先排序结局指标。
  • 纳入570例既往接受过BCG诱导且末次治疗在12个月内的复发高级别NMIBC患者,均适合RC或BST。
  • 371例选择BST,199例选择RC;平均年龄71.4岁,女性占21%。

主要发现

  • RC与更好的情绪功能、总体健康相关生活质量、经济负担及更低的抑郁和焦虑相关。
  • BST与更好的肠道和性健康相关。
  • 癌症特异性生存BST为99%,RC为96%(wRR 0.99,95%CI 0.97至1.01)。
  • RC与更高的不良事件和严重不良事件风险相关,包括90天死亡率2.5%。

临床怎么用

  • 对复发高级别NMIBC且适合两种治疗的候选人,可将RC作为合理选项与BST进行共同决策。
  • 需向患者说明RC在情绪功能和生活质量方面的潜在优势及更高的不良事件风险。
  • 需向患者说明BST在肠道和性健康方面的潜在优势及肿瘤学结局与RC相近。

局限性

  • 为观察性队列研究,治疗由患者选择,存在选择偏倚可能。
  • 随访报告至12个月,长期结局未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer-specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS: Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, -0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION: Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gore JL, Wolff EM, Nash MG, et al. Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. J Clin Oncol. 2025. PMID: 41397208. doi:10.1200/JCO-25-01324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。